The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...
US fast food giant Wendy's has appointed VML as its lead strategic and creative agency Today The Brave in Australia, AdNews can reveal. Lauren Leahy, chief transformation officer at Flynn Group ...
Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback